Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies

Avid Bioservices to Join S&P SmallCap 600 Index

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

Avid Bioservices to Participate at Upcoming Investor Conferences

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors